Vaxxinity – Expansively Disrupting Medicine
Mei Mei Hu, CEO of Vaxxinity, discusses the company’s approach to targeting a wide variety of chronic diseases such as Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia, as well as their COVID-19 booster vaccine. Vaxxinity aims to utilize its unique synthetic peptide platform technology to bring the convenience, efficiency, and cost-effectiveness of vaccines to the treatment and prevention of chronic diseases — making critical medicines available to all. For more information on Vaxxinity visit https://vaxxinity.com.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Alzheimer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Alzheimer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Alzheimer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Mei Mei Hu, CEO of Vaxxinity, discusses the company’s approach to targeting a wide variety of chronic diseases such as Alzheimer’s, Parkinson’s, migraine, and hypercholester…
- Key Point: Vaxxinity aims to utilize its unique synthetic peptide platform technology to bring the convenience, efficiency, and cost-effectiveness of vaccines to the treatment and preventi…
- Key Point: For more information on Vaxxinity visit https://vaxxinity.com.
- Key Point: Mei Mei is Chief Executive Officer and Co-Founder of Vaxxinity and is also a member of the executive committee of United Biomedical, Inc.
- Key Point: She has overseen the launch of one of the first endobody vaccines in the world and the successful spin-out of five companies, including Vaxxinity’s IPO on NASDAQ.
Mei Mei is Chief Executive Officer and Co-Founder of Vaxxinity and is also a member of the executive committee of United Biomedical, Inc. She has overseen the launch of one of the first endobody vaccines in the world and the successful spin-out of five companies, including Vaxxinity’s IPO on NASDAQ. She currently leads an active pipeline of chronic disease immunotherapeutic candidates including for Alzheimer’s, Parkinson’s, and hypercholesterolemia as well as variant-inclusive COVID booster. Mei Mei was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues. Mei Mei is also co-founder of an investment and advisory group with active investments in real estate, energy and life sciences. She has been named to Time 100 Next list, Fortune 40 under 40, and is a member of the Young Global Leaders of World Economic Forum. She holds a B.A. from University of Pennsylvania and her J.D. from Harvard Law School
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

